NCT05377333View on ClinicalTrials.gov

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

June 2, 2022

Primary Completion Date

November 22, 2023

Study Completion Date

November 22, 2023

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

LY3457263

Administered SC.

DRUG

Placebo

Administered SC.

DRUG

Dulaglutide

Administered SC.

Trial Locations (5)

33143

Qps-Mra, Llc, South Miami

36207

Pinnacle Research Group, LLC, Anniston

92801

CenExel ACT, Anaheim

30331 2012

Atlanta Center of Medical Research, Atlanta

08009

CenExel-HRI, Berlin

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY